Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Kryptokur, Lutrelef; Belgium: HRF; Czech Republic: LHRH; France: LHRH, Lutrelef; Germany: Gonavet Veyx Depherelin, Kryptocur, LHRH, Lutrelef, Ovarelin, Relefact LH-RH; Greece: Relefact LHRH; Ireland: HRF; Italy: Kryptocur, Lutrelef; Luxembourg: HRF, Kryptocur; Netherlands: Crytocur, Relefact LH-RH; Poland: Relisorm L, Zyclomat pulse set-Lutrelef; Slovakia: Decapectyl; Sweden: Lutrelef; UK: HRF.

North America

Canada: Lutrepulse, Relisorm.


Japan: Hypocrine, LH-RH.

Drug combinations


Gonadorelin Acetate: C~55~H~75~N~17~O~13~ xC~2~H~4~O~2~ yH~2~O. Gonadorelin acetate is the diacetate salt or a mixture of mono- and diacetate hydrates. (1) Luteinizing hormone-releasing factor acetate hydrate; (2) 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate hydrate. CAS-52699-48-6; CAS-33515-09-2 (gonadorelin)(1975).

Gonadorelin Hydrochloride: C~55~H~75~N~17~O~13~ 2HCl. Mw: 1255.21. 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide hydrochloride. CAS-51952-41-1 (1975).

Pharmacologic Category

Gonadotropins. Diagnostic Agents; Pituitary Function. Gonadotrophic Hormone. (ATC-Code: H01CA01; V04CM01).

Mechanism of action

Stimulates release of luteinizing hormone (LH) from anterior pituitary gland.

Therapeutic use

Evaluation of functional capacity and response of gonadotrophic hormones. Evaluation of abnormal gonadotropin regulation as in precocious puberty and delayed puberty. Treatment of primary hypothalamic amenorrhea. Treatment of one-and two-sided undescended testicles.

Pregnancy and lactiation implications

Unknown whether drug is excreted in breast milk (use caution).

Unlabeled use


Hypersensitivity to gonadorelin or any component of the formulation. Women with any condition that could be exacerbated by pregnancy. Patients with ovarian cysts or causes of anovulation other than those of hypothalamic origin. Any condition that may be worsened by reproductive hormones.

Warnings and precautions

Diluent for injection contains benzyl alcohol (large amounts associated with «gasping syndrome» in neonates). Hypersensitivity and anaphylactic reactions occurred following multiple-dose administration. Use with caution in women in whom pregnancy could worsen pre-existing conditions (e.g. pituitary prolactinemia). Multiple pregnancy possible.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart